## Tarpeyo (budesonide) Prior Authorization Request Form

Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

| MEMBER'S LAST NAME  | i:                         | MEMBER'S FIRST N            | AME:  |  |
|---|----------------------------|-----------------------------|---|--|
|   | eview (e.g., chart notes o | or lab data, to support the | Attach any additional documentation authorization request). Information |  |
|   |                            |                             |   |  |
| MEMBER INFORMATION  | N                          |                             |   |  |
| LAST NAME:  |                            | FIRST NAME:                 | FIRST NAME:   |  |
| PHONE NUMBER:   |                            | DATE OF BIRTH:              |   |  |
| STREET ADDRESS:   |                            |                             |   |  |
| CITY:   |                            | STATE:                      | ZIP CODE:   |  |
| PATIENT INSURANCE   | ID NUMBER:                 |                             |   |  |
| ☐ MALE ☐ FEMALE   | HEIGHT (IN/CM):            | WEIGHT (LB/KG): _           | ALLERGIES:  |  |
| DISCLOSURE AUTHORI<br>FOLLOWING LINK: PRII<br>PATIENT'S AUTHORIZE<br>AUTHORIZED REPRESE | METHERAPEUTICS.CC          | OM/NOPP<br>(IF APPLICABLE): |   |  |
|   |                            |                             |   |  |
| PRESCRIBER INFORM LAST NAME:  | ATION                      | FIRST NAME:                 |   |  |
|   |                            |                             |   |  |
| PRESCRIBER SPECIALTY:   |                            | EMAIL ADDRESS               | EMAIL ADDRESS:  |  |
| NPI NUMBER:   |                            | DEA NUMBER:                 | DEA NUMBER:   |  |
| PHONE NUMBER:   |                            | FAX NUMBER:                 | FAX NUMBER:   |  |
| STREET ADDRESS:   |                            |                             |   |  |
| CITY:   |                            | STATE:                      | ZIP CODE:   |  |
| REQUESTER (if different than prescriber):   |                            | OFFICE CONTAC               | OFFICE CONTACT PERSON:  |  |
|   |                            | 1                           |   |  |
| MEDICATION OR MED   | ICAL DISPENSING INF        | ORMATION                    |   |  |
| MEDICATION NAME:  |                            |                             |   |  |
| DOSE/STRENGTH:  | FREQUENCY:                 | LENGTH OF<br>THERAPY/REFIL  | QUANTITY:   |  |
| ☐ NEW THERAPY   | _                          | IF RENEWAL: DATE TH         |   |  |
| DURATION OF THERAI  | PY (SPECIFIC DATES)        | :                           |   |  |
| Continued on next page  |                            |                             |   |  |

© 2024 Prime Therapeutics Management LLC, a Prime Therapeutics company Prime Therapeutics Management – Commercial Clients. Revision Date: 2.1.2025 CAT009



## Tarpeyo (budesonide) Prior Authorization Request Form

Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

| MEMBER'S LAST NAME:   | MEMBER'S FIRST N                        | AME:                                 |  |  |  |
|---|---|--------------------------------------|--|--|--|
|   | OTHER MEDICATIONS FOR THIS              | CONDITION?                           |  |  |  |
| MEDICATION/THERAPY (SPECIFY DRUG NAME AND DOSAGE):  | DURATION OF THERAPY<br>(SPECIFY DATES): | RESPONSE/REASON FOR FAILURE/ALLERGY: |  |  |  |
| 2. LIST DIAGNOSES:  |   | ICD-10:                              |  |  |  |
| ☐ Primary immunoglobulin A nephr☐ Other diagnosis:  |   |                                      |  |  |  |
| <b>3. REQUIRED CLINICAL INFORMATION:</b> PLEASE PROVIDE ALL RELEVANT CLINICAL INFORMATION TO SUPPORT A PRIOR AUTHORIZATION.   |   |                                      |  |  |  |
| Will the patient be using the drug as a part of the clinical trial? ☐ Yes ☐ No  |   |                                      |  |  |  |
| Was the patient diagnosis of primary immunoglobulin A nephropathy (IgAN) confirmed via renal biopsy? (Documentation required) ☐ Yes ☐ No  |   |                                      |  |  |  |
| Is the patient at risk of rapid disea   | ase progression? (Documentation         | required)?                           |  |  |  |
| Were other causes of immunoglobulin A nephropathy (IgAN), such as but not limited to viral causes, inflammatory bowel disease, ruled out? $\square$ Yes $\square$ No                                    |   |                                      |  |  |  |
| Has the patient been on a maximum tolerate dose of an angiotensin converting enzyme (ACE) inhibitor or a Angiotensin II receptor blocker for at least 3-months? (Documentation required) ☐ Yes ☐ No     |   |                                      |  |  |  |
| If no to the question above, does the patient have an absolute contraindication to angiotensin converting enzyme (ACE) inhibitor or a Angiotensin II receptor blocker? (Documentation required)  Yes No |   |                                      |  |  |  |
| Does the patient have proteinuria of at least 1 gram per day? (Documentation required) ☐ Yes ☐ No   |   |                                      |  |  |  |
| Does the patient have an estimate   | ed eGFR of at least 35 mL/min/1.73      | m2?  Yes No                          |  |  |  |
| Does the patient have a history of failure, contraindication or intolerance to a 30-day trial of a glucocorticoid (e.g., methylprednisolone, prednisone) (documentation required)?   Yes No             |   |                                      |  |  |  |
| Will Filspari (sparsentan) be used in combination with Tarpeyo (budesonide)? ☐ Yes ☐ No   |   |                                      |  |  |  |





## Tarpeyo (budesonide) Prior Authorization Request Form

Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

| MEMBER'S LAST NAME:   | MEMBER'S FIRST NAME:   |  |  |  |
|---|--|--|--|--|
| Is Filspari (sparsentan) being prescribed   | by, or in consultation with, a nephrologist?   Yes  No   |  |  |  |
| Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review? |  |  |  |  |
|   |  |  |  |  |
| Please note: Not all drugs/diagnosis are correquired information is received.   | vered on all plans. This request may be denied unless all  |  |  |  |
| understand that the Health Plan, insurer, Me  | ovided is true and accurate to the best of my knowledge. I edical Group or its designees may perform a routine audit and to verify the accuracy of the information reported on this form.  |  |  |  |
| Prescriber Signature or Electronic I.D. Ve  | erification: Date:   |  |  |  |
| information that is legally privileged. If you a disclosure, copying, distribution, or action ta  | nts accompanying this transmission contain confidential health are not the intended recipient, you are hereby notified that any aken in reliance on the contents of these documents is strictly tion in error, please notify the sender immediately (via return on of these documents. |  |  |  |

**FAX THIS FORM TO:** 800-424-7640

**MAIL REQUESTS TO:** Prime Therapeutics Management Prior Authorization Program

Attn: CP-4201 P.O. Box 64811 St. Paul, MN 55164-0811 **Phone**: 877-228-7909

